SKF 38393 hydrobromide

Name: SKF 38393 hydrobromide
Brand: Tocris Bioscience
SKU: 0922

Tocris Bioscience, part of Bio-Techne | Catalog # 0922

Citations (20)

COA / SDS

Selective D1-like agonist

Key Product Details

Chemical Name:	(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide
Purity:	≥98%
Molecular Weight:	336.23 kDa

View Full Technical Details for SKF 38393 hydrobromide

Technical Data
Citations

Biological Activity for SKF 38393 hydrobromide

SKF 38393 hydrobromide is a prototypical D₁-like dopamine receptor selective partial agonist (K_i values are 1, ~ 0.5, ~ 150, ~ 5000 and ~ 1000 nM for D₁, D₅, D₂, D₃ and D₄ receptors respectively).

Technical Data for SKF 38393 hydrobromide

M. Wt	336.23 kDa
Formula	C₁₆H₁₇NO₂.HBr
Storage	Desiccate at -20°C
Purity	≥98%
CAS Number	20012-10-6

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for SKF 38393 hydrobromide

Solubility

Soluble Soluble to 25 mM in water with gentle warming and to 100 mM in DMSO

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt*

g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1 (C1)

Volume 1 (V1)

Concentration 2 (C2)

Volume 2 (V2)

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

References for SKF 38393 hydrobromide

References are publications that support the biological activity of the product.

Murugan M, Harward S, Scharff C, Mooney R Diminished FoxP2 levels affect dopaminergic modulation of corticostriatal signaling important to song variability. Neuron, 2013;80(6):1464-76. 2013 PMID: 24268418
J Mitlöhner, R Kaushik, H Niekisch, A Blondiaux, CE Gee, MFK Happel, E Gundelfing, A Dityatev, R Frischknec, C Seidenbech Dopamine Receptor Activation Modulates the Integrity of the Perisynaptic Extracellular Matrix at Excitatory Synapses Cells, 2020;9(2):. 2020 PMID: 31972963
Mikulak J, Bozzo L, Roberto A, Pontarini E, Tentorio P, Hudspeth K, Lugli E, Mavilio D Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. J Immunol, 2014;193(6):2792-800. 2014 PMID: 25127864
Geter-Douglass et al. Characterization of unconditioned behavioral effects of DA D₃/D₂ receptor agonists. J.Pharmacol.Exp.Ther., 1997;283:7 PMID: 9336302
Habuchi et al. DA stimulation of cardiac β-adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. Br.J.Pharmacol., 1997;122:1669 PMID: 9422813
Sibley et al. Interactions of novel DArgic ligands with D₁ and D₂ DA receptors. Life Sci., 1982;31:637 PMID: 6127585
Seeman and Van Tol DA receptor pharmacology. Trends Pharmacol.Sci., 1994;15:264 PMID: 7940991